Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

Minoryx announces dosing of the…

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

Ona Therapeutics Strengthens Leadership Team…

Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field

At six months post-grafting surgery…

Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

• Proceeds to support Phase…

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

TUB-040 is a next-generation NaPi2b-targeting…

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

Bagsværd, Denmark, and Hannover, Germany,…

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Financing round co-led by EQT…

Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman

Ghent, Belgium – August 29,…

Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

• Collaboration to make use…

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

US trial with leriglitazone to…